Lycia Therapeutics IPO: $938M Valuation Target, Big Risks
Lycia Therapeutics IPO targets up to a $937.7 million valuation with 14.7 million shares at $16 to $18. Terms, use of proceeds and risks.
Lycia Therapeutics IPO targets up to a $937.7 million valuation with 14.7 million shares at $16 to $18. Terms, use of proceeds and risks.